SCOPUS 정보 검색 플랫폼

Stroke

Volumn 43, Issue 3, 2012, Pages 922-923

Critique of apixaban versus warfarin in patients with atrial fibrillation

(1) Nedeltchev, Krassen a,b

a TRIEMLI HOSPITAL (Switzerland)

b UNIVERSITY OF BERN (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; APIXABAN; DABIGATRAN; PROTEINASE INHIBITOR; RIVAROXABAN; WARFARIN;

ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CARDIAC PATIENT; DRUG FATALITY; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HUMAN; PRIORITY JOURNAL; STROKE; TREATMENT OUTCOME;

ANTICOAGULANTS; ATRIAL FIBRILLATION; CLINICAL TRIALS, PHASE IV AS TOPIC; FIBRINOLYTIC AGENTS; HUMANS; PYRAZOLES; PYRIDONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; TREATMENT OUTCOME; WARFARIN;

EID: 84857589298 PISSN: 00392499 EISSN: 15244628 Source Type: Journal
DOI: 10.1161/STROKEAHA.111.640961 Document Type: Article

Times cited : (4)

References (8)

1
- 80052836882
- A new era for anticoagulation in atrial fibrillation
- Mega JL. A new era for anticoagulation in atrial fibrillation. N Engl J Med. 2011;365:1052-1054.
- (2011) N Engl J Med. , vol.365 , pp. 1052-1054
- Mega, J.L.¹

2
- 80052825103
- Apixaban versus warfarin in patients with atrial fibrillation
- Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992.
- (2011) N Engl J Med. , vol.365 , pp. 981-992
- Granger, C.B.¹ Alexander, J.H.² McMurray, J.J.³ Lopes, R.D.⁴ Hylek, E.M.⁵ Hanna, M.⁶

3
- 70349306707
- Dabigatran versus warfarin in patients with atrial fibrillation
- Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.
- (2009) N Engl J Med. , vol.361 , pp. 1139-1151
- Connolly, S.J.¹ Ezekowitz, M.D.² Yusuf, S.³ Eikelboom, J.⁴ Oldgren, J.⁵ Parekh, A.⁶

4
- 80052592404
- Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
- Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891.
- (2011) N Engl J Med. , vol.365 , pp. 883-891
- Patel, M.R.¹ Mahaffey, K.W.² Garg, J.³ Pan, G.⁴ Singer, D.E.⁵ Hacke, W.⁶

5
- 58149458160
- Apixaban metabolism and pharmacokinetics after oral administration to humans
- Raghavan N, Frost CE, Yu Z, He K, Zhang H, Humphreys WG, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009;37:74-81.
- (2009) Drug Metab Dispos. , vol.37 , pp. 74-81
- Raghavan, N.¹ Frost, C.E.² Yu, Z.³ He, K.⁴ Zhang, H.⁵ Humphreys, W.G.⁶

6
- 76749166335
- In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies
- Wang L, Zhang D, Raghavan N, Yao M, Ma L, Frost CE, et al. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos. 2010;38:448-458.
- (2010) Drug Metab Dispos. , vol.38 , pp. 448-458
- Wang, L.¹ Zhang, D.² Raghavan, N.³ Yao, M.⁴ Ma, L.⁵ Frost, C.E.⁶

7
- 84859004059
- Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: Quantitative benefit-harm and economic analyses
- Pink J, Lane S, Pirmohamed M, Hughes DA. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses. BMJ. 2011;343:d6333.
- (2011) BMJ , vol.343
- Pink, J.¹ Lane, S.² Pirmohamed, M.³ Hughes, D.A.⁴

8
- 84857548094
- Accessed November 29, 2011
- Ben Hirschler. EU backs stroke prevention drug despite 256 deaths. Reuters. Available at: http://www.reuters.com/article/2011/11/18/us- eustrokeidUSTRE7AH1R920111118. Accessed November 29, 2011.
- Ben Hirschler. EU Backs Stroke Prevention Drug Despite 256 Deaths. Reuters

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.